DB:1ME

Stock Analysis Report

Executive Summary

Medifocus, Inc., a medical technology company, develops and commercializes minimally invasive focused heat systems for the treatment of cancerous and benign tumors, and enlarged prostate in Canada and the United States.

Snowflake

Fundamentals

Slightly overvalued with imperfect balance sheet.


Similar Companies

Share Price & News

How has Medifocus's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

1ME

4.5%

DE Medical Equipment

1.4%

DE Market


1 Year Return

-87.5%

1ME

15.2%

DE Medical Equipment

3.7%

DE Market

Return vs Industry: 1ME underperformed the German Medical Equipment industry which returned 15.2% over the past year.

Return vs Market: 1ME underperformed the German Market which returned 3.7% over the past year.


Shareholder returns

1MEIndustryMarket
7 Day0%4.5%1.4%
30 Day400.0%1.4%1.8%
90 Day66.7%1.1%3.4%
1 Year-87.5%-87.5%17.0%15.2%7.0%3.7%
3 Year-87.5%-87.5%101.2%96.0%18.5%8.3%
5 Year-98.9%-98.9%275.6%256.7%42.2%22.9%

Price Volatility Vs. Market

How volatile is Medifocus's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Medifocus undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: 1ME (€0) is trading below our estimate of fair value (€0)

Significantly Undervalued: 1ME is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 1ME is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: 1ME is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate 1ME's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 1ME has negative assets, so we can't compare its PB Ratio to the DE Medical Equipment industry average.


Next Steps

  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Medifocus forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

12.8%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Medifocus has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Medifocus performed over the past 5 years?

37.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: 1ME is unprofitable, but has reduced losses over the past 5 years at a rate of 37.3% per year.

Accelerating Growth: Unable to compare 1ME's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 1ME is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (6.4%).


Return on Equity

High ROE: 1ME's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets

ROA vs Industry: 1ME is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: 1ME is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Medifocus's financial position?


Financial Position Analysis

Short Term Liabilities: 1ME has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: 1ME has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: 1ME has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: 1ME's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: 1ME has a low level of unsold assets or inventory.

Debt Coverage by Assets: 1ME has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable 1ME has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: 1ME is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 117.6% per year.


Next Steps

Dividend

What is Medifocus's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.4%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate 1ME's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 1ME's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if 1ME's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 1ME's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 1ME's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of Medifocus's salary, the management and board of directors tenure and is there insider trading?

10.9yrs

Average management tenure


CEO

William Jow (61yo)

3yrs

Tenure

US$180,000

Compensation

Dr. William W. Jow, M.D., has been the Chief Executive Officer of Medifocus Inc. since October 1, 2016. Dr. Jow has been President of Medifocus Inc. since March 2016. He served as Medical Director of Medif ...


CEO Compensation Analysis

Compensation vs. Market: William's total compensation ($USD180.00K) is about average for companies of similar size in the German market ($USD216.74K).

Compensation vs Earnings: William's compensation has been consistent with company performance over the past year.


Management Age and Tenure

10.9yrs

Average Tenure

61yo

Average Age

Experienced Management: 1ME's management team is seasoned and experienced (10.9 years average tenure).


Board Age and Tenure

10.9yrs

Average Tenure

66yo

Average Age

Experienced Board: 1ME's board of directors are seasoned and experienced ( 10.9 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Mirsad Jakubovic (57yo)

    Chief Financial Officer

    • Tenure: 10.9yrs
    • Compensation: US$20.00k
  • Charkes Shelton (73yo)

    Executive Vice President and General Counsel

    • Tenure: 10.9yrs
  • William Jow (61yo)

    CEO, President & Director

    • Tenure: 3yrs
    • Compensation: US$180.00k
  • Stuart Katz

    Vice President of Operations

    • Tenure: 0yrs

Board Members

  • Guy Ely (66yo)

    Member of the Scientific Advisory Board

    • Tenure: 10.9yrs
  • Augustine Chow (66yo)

    Director

    • Tenure: 11.2yrs
    • Compensation: US$21.00k
  • Grant Walsh (70yo)

    Chairman of Board of Directors

    • Tenure: 11.2yrs
    • Compensation: US$21.00k
  • Joseph Chan (73yo)

    Director

    • Tenure: 11.2yrs
    • Compensation: US$21.00k
  • Mark Dewhirst

    Member of the Scientific Advisory Board

    • Tenure: 10.9yrs
  • Chire Holloway

    Member of the Scientific Advisory Board

    • Tenure: 10.9yrs
  • Eric Lwowski

    Member of the Scientific Advisory Board

    • Tenure: 10.9yrs
  • Joe Chalil (46yo)

    Member of Strategic Advisory Board

    • Tenure: 4.3yrs
  • Raymond C. Tong (60yo)

    Director

    • Tenure: 4.8yrs
    • Compensation: US$21.00k
  • William Jow (61yo)

    CEO, President & Director

    • Tenure: 3yrs
    • Compensation: US$180.00k

Company Information

Medifocus Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Medifocus Inc.
  • Ticker: 1ME
  • Exchange: DB
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$610.447k
  • Listing Market Cap: US$547.998k
  • Shares outstanding: 184.98m
  • Website: https://www.medifocusinc.com

Number of Employees


Location

  • Medifocus Inc.
  • The Exchange Tower
  • PO Box 427
  • Toronto
  • Ontario
  • M5X 1E3
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MFSTSXV (TSX Venture Exchange)YesCommon SharesCACADNov 2008
MDFZ.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDNov 2008
1MEDB (Deutsche Boerse AG)YesCommon SharesDEEURNov 2008

Biography

Medifocus, Inc., a medical technology company, develops and commercializes minimally invasive focused heat systems for the treatment of cancerous and benign tumors, and enlarged prostate in Canada and the  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/18 21:41
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.